BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX), 'we await further derisking data'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $124.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
